For the first time, fundamental tumor phenotypes determined by a simple blood test Single test now provides molecular tumor typing, subtyping and confirmation of absence of actionable biomarkers to ...

Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, ...

Utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies. Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate endpoint to monitor ...

Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer ...